Altimmune, Inc. (ALT)

NGM – Real vaqt narxi. Valyuta: USD

3.16

+0.17 (5.50%)

Bozor ochiq: Aug 12, 2026, 12:27 PM EDT

3.04

+0.04 (1.18%)

Oldingi bozordan keyin: Aug 11, 2026, 7:57 PM EDT

05.08.2026

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026.

03.08.2026

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomes

Videolar

No Data

There is no data to display

Press-relizlar

03.08.2026

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomes

Altimmune, Inc. (ALT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Altimmune, Inc. (ALT)

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Videolar

No Data

Press-relizlar

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Videolar

No Data

Press-relizlar

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Search stocks

Altimmune, Inc. (ALT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Altimmune, Inc. (ALT)

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Videolar

No Data

Press-relizlar

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Videolar

No Data

Press-relizlar

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH